Atomoxetine News and Research

RSS

Atomoxetine drug may restore memory deficits in menopausal women

Memory lapses and changes in mental functions occur naturally as we get older. But for many women going through menopause, these memory lapses occur more frequently.

17 Feb 2012

ADHD drugs not bad for the heart: Study

Drugs widely prescribed for attention disorders like Ritalin, Adderall and other drugs, did not increase the risk of serious heart problems in a major study published Monday. This could assure parents of children on these medications on heart-related safety of the medicines.

12 Dec 2011

Parent behavior training can effectively treat ADHD in young children

Formal training in parenting strategies is a low-risk, effective method for improving behavior in preschool-age children at risk for developing attention deficit hyperactivity disorder (ADHD), while there is less evidence supporting the use of medications for children younger than 6 years old, according to a new report from the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ).

27 Oct 2011

U.S. appeals court rules in favor of Lilly over Strattera patent case

Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has overturned a prior ruling by the U.S. District Court for the District of New Jersey and has upheld the validity of the company's method-of-use patent on Strattera.

30 Jul 2011

Amphetamines can control ADHD symptoms in adults

Giving amphetamines to adults with Attention Deficit Hyperactivity Disorder (ADHD) can help them control their symptoms, but the side effects mean that some people do not manage to take them for very long.

27 Jul 2011

FDA approves Atomoxetine HCl capsules for ADHD

Actavis has received approval from the U.S. Food & Drug Administration to market Atomoxetine HCl capsules for the treatment of attention deficit/hyperactivity disorder (ADHD).

2 Sep 2010

USFDA grants Sun Pharma subsidiary approval for generic Strattera capsules ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Strattera ®, atomoxetine hydrochloride capsules.

2 Sep 2010

Eli Lilly to appeal against U.S. District Court ruling in Strattera patent litigation

Eli Lilly and Company today announced that the U.S. District Court for the District of New Jersey has ruled against the company in its patent litigation for Strattera. In the case of Eli Lilly and Company v. Actavis Elizabeth LLC, et al, the court ruled that Lilly's '590 patent, or method-of-use patent, for Strattera is invalid. The patent had been set to expire in May of 2017.

13 Aug 2010

FDA approves Strattera for ADHD in children and adolescents

Eli Lilly and Company announced today that the United States Food and Drug Administration (FDA) has approved Strattera (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.

8 May 2008

Growth in ADHD medication use due to improved ADHD identification in adult and female patients

Attention deficit hyperactivity disorder (ADHD) has been traditionally viewed as a childhood disorder, while ADHD in adults has been underdiagnosed and undertreated.

8 Jun 2007

UIC study evaluates two medications for ADHD

University of Illinois at Chicago researchers are comparing two drugs commonly used to treat attention deficit hyperactivity disorder to determine if genetic factors predict which children will respond to either or both drugs.

7 Nov 2006

New advice about the use of Strattera (atomoxetine)

New advice to doctors and patients about the use of Strattera, (atomoxetine), was issued today by the Medicines and Healthcare products Regulatory Agency, (MHRA).

3 Feb 2005

Treatment with Strattera makes children with ADHD fall asleep faster

Twice daily treatment with Strattera® (atomoxetine HCl), approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), showed children with ADHD fell asleep faster compared to three-times daily treatment with methylphenidate

29 Jun 2004

Guidelines include Strattera as an ADHD therapy option

The American Academy of Child and Adolescent Psychiatry (AACAP), the leading professional organization for child and adolescent psychiatry, today issued guidelines that highlight the importance of accurate diagnosis and appropriate treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).

27 Apr 2004